Contemporary Anticoagulation Practices for Postoperative Atrial Fibrillation: A Single Center Experience.

Q3 Medicine
Journal of atrial fibrillation Pub Date : 2020-12-31 eCollection Date: 2020-12-01 DOI:10.4022/jafib.2443
Fady S Riad, Konstantin German, Sarah Deitz, Jayakumar Sahadevan, Varun Sundaram, Albert L Waldo
{"title":"Contemporary Anticoagulation Practices for Postoperative Atrial Fibrillation: A Single Center Experience.","authors":"Fady S Riad,&nbsp;Konstantin German,&nbsp;Sarah Deitz,&nbsp;Jayakumar Sahadevan,&nbsp;Varun Sundaram,&nbsp;Albert L Waldo","doi":"10.4022/jafib.2443","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Postoperative atrial fibrillation (POAF) is a frequent in-hospital complication after cardiac surgery. Surprisingly, despite its prevalence, management of this condition has not been well studied. One promising approach that has been evaluated in a limited number of studies is use of anticoagulation. However, the trends and patterns of real-world use of anticoagulation in POAF patients has not been systemically investigated. In this study, we aimed to determine real-world patterns of anticoagulation use for patients with POAF.</p><p><strong>Methods: </strong>We identified 200 patients undergoing coronary artery bypass (CABG) or cardiac valve surgery at University Hospitals Cleveland Medical Center over a 2 year period beginning January 2016 with new onset POAF. We reviewed charts to verify candidacy for inclusion in the study and to extract data on anticoagulation use, adverse outcomes, and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores.</p><p><strong>Results: </strong>Anticoagulation use was low after CABG, but high after bioprosthetic valve surgery. The most common anticoagulant used was warfarin. Anticoagulation use was not correlated with CHA<sub>2</sub>DS<sub>2</sub>-VASc score or cardioversion. Stroke and mortality were higher among patients not receiving anticoagulation, however, confirmation of this finding in larger randomized studies is warranted.</p><p><strong>Conclusions: </strong>Anticoagulation use is low after CABG and this practice does not appear to be affected by CHA<sub>2</sub>DS<sub>2</sub>VASc score or cardioversion. This differs with previously reported provider attitudes towards management of this condition. Stroke and mortality appear to be elevated for patients not receiving anticoagulation but further investigation is required to confirm this observation.</p>","PeriodicalId":15072,"journal":{"name":"Journal of atrial fibrillation","volume":"13 4","pages":"2443"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691297/pdf/jafib-13-02443.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of atrial fibrillation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4022/jafib.2443","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/12/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Aims: Postoperative atrial fibrillation (POAF) is a frequent in-hospital complication after cardiac surgery. Surprisingly, despite its prevalence, management of this condition has not been well studied. One promising approach that has been evaluated in a limited number of studies is use of anticoagulation. However, the trends and patterns of real-world use of anticoagulation in POAF patients has not been systemically investigated. In this study, we aimed to determine real-world patterns of anticoagulation use for patients with POAF.

Methods: We identified 200 patients undergoing coronary artery bypass (CABG) or cardiac valve surgery at University Hospitals Cleveland Medical Center over a 2 year period beginning January 2016 with new onset POAF. We reviewed charts to verify candidacy for inclusion in the study and to extract data on anticoagulation use, adverse outcomes, and CHA2DS2-VASc scores.

Results: Anticoagulation use was low after CABG, but high after bioprosthetic valve surgery. The most common anticoagulant used was warfarin. Anticoagulation use was not correlated with CHA2DS2-VASc score or cardioversion. Stroke and mortality were higher among patients not receiving anticoagulation, however, confirmation of this finding in larger randomized studies is warranted.

Conclusions: Anticoagulation use is low after CABG and this practice does not appear to be affected by CHA2DS2VASc score or cardioversion. This differs with previously reported provider attitudes towards management of this condition. Stroke and mortality appear to be elevated for patients not receiving anticoagulation but further investigation is required to confirm this observation.

当代房颤术后抗凝实践:单中心经验。
目的:术后心房颤动(POAF)是心脏手术后常见的院内并发症。令人惊讶的是,尽管它很普遍,但对这种情况的管理尚未得到很好的研究。在有限数量的研究中评估的一种有希望的方法是使用抗凝。然而,POAF患者实际使用抗凝治疗的趋势和模式尚未进行系统调查。在这项研究中,我们旨在确定POAF患者抗凝使用的现实模式。方法:从2016年1月开始,我们在克利夫兰医学中心大学医院确定了200例新发POAF患者,他们接受了冠状动脉搭桥术(CABG)或心脏瓣膜手术。我们回顾了图表以验证纳入研究的候选资格,并提取了抗凝使用、不良结局和CHA2DS2-VASc评分的数据。结果:冠状动脉搭桥术后抗凝使用率低,生物瓣膜置换术后抗凝使用率高。最常用的抗凝剂是华法林。抗凝使用与CHA2DS2-VASc评分或心律转复无关。然而,未接受抗凝治疗的患者中风和死亡率更高,这一发现在更大规模的随机研究中得到了证实。结论:冠状动脉搭桥后抗凝使用率低,这种做法似乎不受CHA2DS2VASc评分或转复的影响。这与先前报道的提供者对这种情况的管理态度不同。未接受抗凝治疗的患者中风和死亡率似乎升高,但需要进一步的研究来证实这一观察结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of atrial fibrillation
Journal of atrial fibrillation Medicine-Cardiology and Cardiovascular Medicine
CiteScore
1.40
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信